Status:

ACTIVE_NOT_RECRUITING

Single Fraction Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Non-small Cell Lung Cancer

Lead Sponsor:

Roswell Park Cancer Institute

Conditions:

Lung Non-Small Cell Carcinoma

Positive Surgical Margin

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

This trial studies the side effects of single fraction stereotactic body radiation therapy after surgery in treating patients with non-small cell lung cancer. Standard radiation for lung cancer involv...

Detailed Description

PRIMARY OBJECTIVES: I. Assess feasibility and toxicity of single-fraction stereotactic body radiation therapy (SBRT) in the post-operative setting. SECONDARY OBJECTIVES: I. Assess quality of life f...

Eligibility Criteria

Inclusion

  • Have an Eastern Cooperative Oncology Group (ECOG) performance status =\< 2
  • Has completed curative-intent surgical resection of lung primary with pathologic diagnosis of NSCLC disease, with pathology to include at least 1 of the following:
  • Close (\<=2 mm) or Positive surgical margin (R1/R2) or pathologic N2 disease (with or without extracapsular extension \[ECE\])
  • Anatomic pulmonary resection (lobectomy or pneumonectomy) preferred, although sublobar resection is allowed at the discretion of the treating surgeon. Systemic lobe-specific nodal sampling is required. A minimum of 3 N2 stations must be sampled. Selective lymph node dissection should be completed for patients with known N2 disease
  • Women of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence)
  • Patient or legal representative must be willing and able to participate in protocol requirements, including pre- and post-treatment survey evaluations and clinical assessments
  • Patient or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure

Exclusion

  • Contraindication to SBRT
  • This includes the inability to cooperate with any aspect of SBRT such as the inability to lie still and breath reproducibly
  • Prior radiation therapy targeting the same area for which radiation treatment is being planned
  • Pregnant or nursing female patients
  • Unwilling or unable to follow protocol requirements
  • Any condition which, in the investigator?s opinion, deems the patient unable to participate in enrollment
  • Patients who undergo sublobar resection but are unable to undergo appropriate N1 and N2 lymph node sampling

Key Trial Info

Start Date :

December 4 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 27 2025

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT04073745

Start Date

December 4 2019

End Date

December 27 2025

Last Update

September 10 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Roswell Park Cancer Institute

Buffalo, New York, United States, 14263